###### 

Efficacy and safety of 12 or 24-week 3D+RBV in HCV/HIV coinfected patients subgrouped by HIV ART regimen

  ------------------------------------------------------------------------------------------------------------------------------
                                                     12-week 3D + RBV   12-week 3D + RBV   24-week 3D + RBV   24-week 3D + RBV
  -------------------------------------------------- ------------------ ------------------ ------------------ ------------------
  Parameter, n/N (%)                                 ATV                RAL                ATV                RAL

  SVR4                                               15/16 (93.8)       14/15 (93.3)       12/12 (100)        19/20 (95.0)

  SVR12                                              15/16 (93.8)       14/15 (93.3)       NA                 NA

  **Adverse events and laboratory abnormalities**\   \                  \                  \                  \
  Ocular icterus\                                    \                  \                  \                  \
  Jaundice                                           5/16 (31.3)\       0\                 1/12 (8.3)\        0\
                                                     2/16 (12.5)        0                  0                  0

  Total bilirubin\                                   \                  \                  \                  \
  Grade 3\                                           8/16 (50.0)\       2/15 (13.3)\       6/12 (50.0)\       0\
  Grade 4                                            1/16 (6.3)         0                  0                  0

  Aspartate aminotransferase\                        \                  \                  \                  \
  Grade 3\                                           0\                 0\                 0\                 1/20 (5.0)\
  Grade 4                                            0                  0                  0                  0
  ------------------------------------------------------------------------------------------------------------------------------
